University of California San Francisco

Publications

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 137
Data provided by UCSF Profiles, powered by CTSI
  1. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
     Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA
    2024 | View in PubMed
  2. Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy.
     Nadine Goldhammer, Shruti Warhadpande, Liana Beld, Cristian K. Maldonado Rodas, Allison Lam, Tam Binh Bui, Shoko Emily Abe, Michael Alvarado, Cheryl Ewing, Karen Goodwin, Rita Mukhtar, Jasmine Wong, Lamorna Brown Swigart, Gillian Hirst, Christopher Schwartz, Laura van't Veer, Laura Esserman, Jo Chien, Jennifer M. Rosenbluth
    2024 | View in PubMed
  3. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma.
     Chen JJ, Zhu I, Patel A, Krings G, Chen YY, Yuen F, Mukhtar RA, Melisko M, Singer L, Park CC, Prionas ND
    2024 | View in PubMed
  4. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk.
     Northey JJ, Hayward MK, Yui Y, Stashko C, Kai F, Mouw JK, Thakar D, Lakins JN, Ironside AJ, Samson S, Mukhtar RA, Hwang ES, Weaver VM
    2024 | View in PubMed
  5. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
     Parmeshwar N, Dugan CL, Barnes LL, Cheng JK, Patterson AK, Miller A, Mukhtar R, Piper M
    2024 | View in PubMed
  6. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
     Schwartz CJ, Khorsandi N, Blanco A, Mukhtar RA, Chen YY, Krings G
    2023 | View in PubMed
  7. ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
     Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M, Mukhtar RA
    2023 | View in PubMed
  8. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
     Record H, Clelland E, Rothschild HT, Kaur M, Chien AJ, Melisko M, Rugo HS, Mujir F, Huppert L, Mukhtar RA
    2023 | View in PubMed
  9. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns".
     Mukhtar RA, Huppert L, Ramalingam K
    2023 | View in PubMed
  10. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
     Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA
    2023 | View in PubMed
  11. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
     S. Gottipati, H.M. Earl, C. Yau, D.A. Cameron, J. Abraham, L. Hayward, F. Reyal, M. Osdoit, G.S. Sonke, J. Wesseling, J. Boughey, M.P. Goetz, A. DeMichele, L. Pusztai, P. Sharma, M. Martin Jimenez, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, F. Symmans, R. Mukhtar
    2023 | View in PubMed
  12. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.
     Rothschild HT, Jo Chien A, Jankowitz RC, Magbanua MJ, Mouabbi JA, Shatsky RA, Levine J, Mukhtar RA
    2023 | View in PubMed
  13. Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
     Parmeshwar N, Dugan CL, Barnes LL, Cheng JK, Patterson AK, Miller A, Mukhtar R, Piper M
    2023 | View in PubMed
  14. ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma.
     Ramalingam K, Mukhtar R
    2023 | View in PubMed
  15. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
     Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M, Mukhtar RA
    2023 | View in PubMed
  16. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
     Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA
    2023 | View in PubMed
  17. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
     Clelland EN, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Benz CC, Mukhtar RA
    2023 | View in PubMed
  18. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
     Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA
    2023 | View in PubMed
  19. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
     Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, Alvarado M, Ewing C, Mukhtar RA
    2023 | View in PubMed
  20. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast.
     Rothschild HT, Mukhtar RA
    2023 | View in PubMed
  21. Editorial: Contrast mammography-a promising tool for the pre-operative evaluation of lobular breast cancer.
     Jochelson MS, Mukhtar RA
    2023 | View in PubMed
  22. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
     Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA
    2023 | View in PubMed
  23. Metabolic Positron Emission Tomography in Breast Cancer.
     Cecil K, Huppert L, Mukhtar R, Dibble EH, O'Brien SR, Ulaner GA, Lawhn-Heath C
    2023 | View in PubMed
  24. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
     Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, ISPY-2 Locoregional Working Group
    2023 | View in PubMed
  25. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
     Mukhtar RA, Yau C, Esserman LJ
    2023 | View in PubMed
  26. Time to Surgery in Breast Cancer-Is Faster Always Better?
     Mukhtar RA, Esserman LJ
    2023 | View in PubMed
  27. 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study.
     Elle N Clelland, Judy Gonzalez-Vargas, Sarah G Palilla, Suneil K Koliwad, Heather I Greenwood, Christopher J Schwartz, Chris C. Benz, Diana L Alba, Rita A Mukhtar
    2023 | View in PubMed
  28. 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression.
     Harriet T Rothschild, A Jo Chien, Rachel C Jankowitz, Mark JM Magbanua, Jason A Mouabbi, Rebecca A Shatsky, Julia Levine, Rita A Mukhtar
    2023 | View in PubMed
  29. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
     Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Mukhtar RA
    2023 | View in PubMed
  30. Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
     Harriet T. Rothschild, Elle Clelland, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, Mary Kathryn Abel, W. Fraser Symmans, Christopher J. Schwartz, Rita Mukhtar
    2023 | View in PubMed
  31. Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
     Elle Clelland, Harriet T. Rothschild, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, Mary Kathryn Abel, W. Fraser Symmans, Jo Chien, Christopher J. Schwartz, Rita Mukhtar
    2023 | View in PubMed
  32. Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).
     Jennifer Rosenbluth, Christopher J. Schwartz, Tam Binh Bui, Shruti Warhadpande, Pravin Phadatare, Sigal Eini, Michael Bruck, Julissa Molina-Vega, Kami Pullakhandam, Nicole Schindler, Lamorna A. Brown Swigart, Christina Yau, Gillian Hirst, Rita Mukhtar, Karthik V. Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Cheryl A. Ewing, Jasmine M. Wong, Michael D. Alvarado, Laura Van’t Veer, Laura J. Esserman, Jo Chien
    2023 | View in PubMed
  33. Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival.
     Mandeep Kaur, Anne Patterson, Julissa Molina-Vega, Harriet T. Rothschild, Elle Clelland, Mary Kathryn Abel, Laura J. Esserman, Olufunmilayo I. Olopade, Rita Mukhtar
    2023 | View in PubMed
  34. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
     Schwartz CJ, Ruiz J, Bean GR, Sirohi D, Joseph NM, Hosfield EM, Jacobs TW, Mukhtar RA, Chen YY, Krings G
    2023 | View in PubMed
  35. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
     Barnes LL, Foster R, Mukhtar RA, Esserman LJ, Ewing C, Alvarado M, Wong J, Piper M
    2023 | View in PubMed
  36. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
     Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ
    2022 | View in PubMed
  37. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education.
     Conroy PC, Mohamedaly S, Karimzada M, Brian R, Im C, Hernandez S, Roman S, Hirose K, Mukhtar R, Kirkwood K, O'Sullivan P, Alseidi A
    2022 | View in PubMed
  38. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
     Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA
    2022 | View in PubMed
  39. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
     Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA
    2022 | View in PubMed
  40. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
     Alison S Baskin, Anne K Patterson, Amie M Blanco, Julie S Mak, Rita A Mukhtar
    2022 | View in PubMed
  41. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
     Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, Jones EF, Mukhtar RA
    2022 | View in PubMed
  42. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
     Tasce Bongiovanni, Elizabeth Lancaster, Hannah Decker, Rita A. Mukhtar, Marisa Schwab, Jeanette Broering, Patricia O’Sullivan, Kenzo Hirose, Elizabeth Wick
    2022 | View in PubMed
  43. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
     Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA
    2022 | View in PubMed
  44. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
     Abel MK, Mukhtar RA
    2022 | View in PubMed
  45. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
     Jason J. Northey, Yoshihiro Yui, Mary-Kate Hayward, Connor Stashko, FuiBoon Kai, Janna Mouw, Dhruv Thakar, Jonathon Lakins, Alastair Ironside, Susan Samson, Rita Mukhtar, E. Shelley Hwang, Valerie Weaver
    2022 | View in PubMed
  46. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
     Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman
    2022 | View in PubMed
  47. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
     Mukhtar R, Symmans WF, Esserman LJ
    2022 | View in PubMed
  48. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
     Greenberg AL, Sullins VF, Donahue TR, Sundaram VM, Saldinger PF, Divino CM, Anton NE, Stefanidis D, Reilly LM, Egan RJ, Beals CKJ, Riall TS, Duh QY, Mukhtar RA, Hirose K, Lebares CC
    2022 | View in PubMed
  49. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
     A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman
    2022 | View in PubMed
  50. Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
     Silver Alkhafaji, Denise Wolf, Mark Magbanua, Laura Van 't Veer, John Park, Laura J. Esserman, Rita A. Mukhtar
    2022 | View in PubMed
  51. Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
     Ella F Jones, Deep K Hathi, Natalia Konovalova, Julissa Molina-Vega, David C Newitt, Courtney Lawhn-Heath, Kimberly M Ray, Bonnie N Joe, Diane Heditsian, Susie Brain, A. Jo Chien, Laura J Esserman, Nola M Hylton, Rita A Mukhtar
    2022 | View in PubMed
  52. Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
     Ella F. Jones, Deep K. Hathi, Julissa Molina-Vega, David C. Newitt, Courtney Lawhn-Heath, Kimberly M. Ray, Bonnie N. Joe, Diane Heditsian, Susie Brain, Rita A. Mukhtar, A. Jo Chien, Hope S. Rugo, Laura J. Esserman, Nola M. Hylton
    2022 | View in PubMed
  53. Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
     Anika Christofferson, Elissa Price, Rita A Mukhtar, Amrita Basu, Laura Esserman, A Jo Chien
    2022 | View in PubMed
  54. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
     Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA
    2021 | View in PubMed
  55. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR.
     Naila Dhanani, Oscar Olavarria, Kyung Hyun Lee, Charlotte Young, Frank Primus, Rita Mukhtar, Julie Holihan, Mike Liang, Hobart Harris
    2021 | View in PubMed
  56. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
     Rothschild HT, Abel MK, Patterson A, Goodman K, Shui A, van Baelen K, Desmedt C, Benz C, Mukhtar RA
    2021 | View in PubMed
  57. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
     Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA
    2021 | View in PubMed
  58. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
     Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ
    2021 | View in PubMed
  59. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
     Khoury AL, Keane H, Varghese F, Hosseini A, Mukhtar R, Eder SE, Weinstein PR, Esserman LJ
    2021 | View in PubMed
  60. Correction to: Applications of 3D printing in breast cancer management.
     Galstyan A, Bunker MJ, Lobo F, Sims R, Inziello J, Stubbs J, Mukhtar R, Kelil T
    2021 | View in PubMed
  61. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
     Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA
    2021 | View in PubMed
  62. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.
     Mary Kathryn Abel, Michelle E. Melisko, Hope S. Rugo, Amy Jo Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura Esserman, Hala Borno, Rita A. Mukhtar
    2021 | View in PubMed
  63. Early onset, multiple, bilateral fibroadenomas of the breast: a case report.
     Im CJ, Miller A, Balassanian R, Mukhtar RA
    2021 | View in PubMed
  64. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions.
     Rita A. Mukhtar, A. Jo Chien
    2021 | View in PubMed
  65. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial.
     Harris HW, Primus F, Young C, Carter JT, Lin M, Mukhtar RA, Yeh B, Allen IE, Freise C, Kim E, Sbitany H, Young DM, Hansen S
    2021 | View in PubMed
  66. Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
     Tang A, Cohan CM, Hansen KS, Beattie G, Greenwood HI, Mukhtar RA
    2021 | View in PubMed
  67. ASO Author Reflections: Changes in Primary Treatment Strategy for Invasive Lobular Carcinoma Highlight the Need for Better Predictors of Therapy Response.
     Mukhtar RA, Boughey JC
    2021 | View in PubMed
  68. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
     Mukhtar RA, Hoskin TL, Habermann EB, Day CN, Boughey JC
    2021 | View in PubMed
  69. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
     Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA
    2021 | View in PubMed
  70. Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS.
     Heather Greenwood, Rita Freimanis, Case Brabham, Rita Mukhtar, Gillian Hirst, Paul Kim, April Liang, Laura Esserman, Nola Hylton, Amrita Basu
    2021 | View in PubMed
  71. Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy.
     Geraldine Tran, Ella Jones, Wen Li, Kelly Fahrner-Scott, David Newitt, Bonnie Joe, Laura Esserman, Nola Hylton, Rita Mukhtar
    2021 | View in PubMed
  72. Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up.
     Case Brabham, Rita Mukhtar, April Liang, Paul Kim, Gillian Hirst, Amrita Basu, Heather Greenwood, Rita Freimanis, Alexander Borowsky, Shelley Hwang, Rick Baehner, Gregor Krings, Nola Hylton, Laura Esserman
    2021 | View in PubMed
  73. Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast.
     Harriet Rothschild, Laura Esserman, Christopher Benz, Rita Mukhtar
    2021 | View in PubMed
  74. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
     Scheepens JCC, Veer LV', Esserman L, Belkora J, Mukhtar RA
    2021 | View in PubMed
  75. Applications of 3D printing in breast cancer management.
     Galstyan A, Bunker MJ, Lobo F, Sims R, Inziello J, Stubbs J, Mukhtar R, Kelil T
    2021 | View in PubMed
  76. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
     Hansen KS, Ghersin H, Piper M, Tavakol M, Lee B, Esserman LJ, Roberts JP, Freise C, Ascher NL, Mukhtar RA
    2021 | View in PubMed
  77. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
     Mukhtar RA, Brabham CE, Guo R, Abel MK, Wong J, Ewing C, Esserman LJ, Alvarado M
    2021 | View in PubMed
  78. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
     Northey JJ, Barrett AS, Acerbi I, Hayward MK, Talamantes S, Dean IS, Mouw JK, Ponik SM, Lakins JN, Huang PJ, Wu J, Shi Q, Samson S, Keely PJ, Mukhtar RA, Liphardt JT, Shepherd JA, Hwang ES, Chen YY, Hansen KC, Littlepage LE, Weaver VM
    2020 | View in PubMed
  79. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
     Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA
    2020 | View in PubMed
  80. 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials.
     M.K. Abel, I. Diaz, J. Levine, L. Pate, E. Viggiano, M. Melisko, R. Mukhtar
    2020 | View in PubMed
  81. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
     Abel MK, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Park C, Mukhtar RA
    2020 | View in PubMed
  82. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
     Abel MK, Brabham CE, Guo R, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Mukhtar RA
    2020 | View in PubMed
  83. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
     Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM
    2020 | View in PubMed
  84. 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast.
     Mary Kathryn Reed Abel, Jasmine Wong, Michael Alvarado, Cheryl Ewing, Laura J. Esserman, Catherine Park, Rita A. Mukhtar
    2020 | View in PubMed
  85. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
     Ruby Guo, Case E. Brabham, Kelly Fahrner-Scott, Mary Kathryn Abel, Jasmine Wong, Michael Alvarado, Laura Esserman, Cheryl Ann Ewing, Rita A. Mukhtar
    2020 | View in PubMed
  86. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
     Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H
    2020 | View in PubMed
  87. Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB).
     Rita A Mukhtar, Tanya L. Hoskin, Elizabeth B. Habermann, Judy C. Boughey
    2020 | View in PubMed
  88. Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study.
     Thomas O'Keefe, Christina Yau, Eliza Jeong, Emma Iaconetti, Paul Kim, Ann Griffin, Joseph McGuire, Rita Mukhtar, Laura Esserman, Olivier Harismendy, Gillian L. Hirst
    2020 | View in PubMed
  89. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy.
     Paul Kim, Heather I. Greenwood, Rita I. Freimanis, Gillian L Hirst, Megan Fischer-Colbrie, Jessica Gibbs, Nola M Hylton, Christina Yau, Eun-Sil Shelley Hwang, Laura J. Esserman, Rita A Mukhtar
    2020 | View in PubMed
  90. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast.
     Kelly Fahrner-Scott, Jasmine M Wong, Merisa Piper, Cheryl Ewing, Michael Alvarado, Laura J Esserman, Nola Hylton, Rita A Mukhtar
    2020 | View in PubMed
  91. Pragmatic Trials and Approaches to Transforming Care.
     Peter G. Stock, Rita Mukhtar, Hila Ghersin, Allison Stover Fiscalini, Laura Esserman
    2020 | View in PubMed
  92. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
     Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS
    2019 | View in PubMed
  93. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
     Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, Mukhtar RA
    2019 | View in PubMed
  94. Editorial: Applying Margin Consensus Guidelines to Invasive Lobular Carcinoma of the Breast.
     Mukhtar RA
    2019 | View in PubMed
  95. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
     Greenwood HI, Wong JM, Mukhtar RA, Alvarado MD, Price ER
    2019 | View in PubMed
  96. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
     Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM
    2019 | View in PubMed
  97. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
     Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR
    2019 | View in PubMed
  98. Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction.
     Michael Holland, Rachel Lentz, Clara Gomez-Sanchez, Jami Rothman, Jasmine Wong, Rita Mukhtar, Hani Sbitany
    2019 | View in PubMed
  99. Changes in mammographic density following bariatric surgery.
     Hosseini A, Khoury AL, Varghese F, Carter J, Wong JM, Mukhtar RA
    2019 | View in PubMed
  100. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast.
     KE Fahrner-Scott, JM Wong, M Piper, C Ewing, M Alvarado, LJ Esserman, N Hylton, RA Mukhtar
    2019 | View in PubMed
  101. Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain.
     HJ Keane, AL Khoury, A Hosseini, FP Varghese, R Mukhtar, SE Eder, J Wong, LJ Esserman
    2019 | View in PubMed
  102. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
     EF Jones, KM Ray, R Mukhtar, W Li, BL Franc, LJ Esserman, BN Joe, MH Pampaloni, NM Hylton
    2019 | View in PubMed
  103. Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.
     Z Zhu, C Yau, AJ Chien, T Haddad, LJ Esserman, L van't Veer, RA Mukhtar
    2019 | View in PubMed
  104. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
     Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators
    2019 | View in PubMed
  105. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
     Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, Esserman L, Mukhtar R, Finlayson E
    2018 | View in PubMed
  106. ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
     Mukhtar RA
    2018 | View in PubMed
  107. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
     Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators
    2018 | View in PubMed
  108. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
     Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M, Sbitany H, Alvarado M, Foster R, Ewing C, Esserman L
    2018 | View in PubMed
  109. 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast.
     M. Mamounas, J. Wong, K. Fahrner-Scott, Y.Y. Chen, G. Krings, C. Ewing, L. Esserman, M. Alvarado, H. Rugo, R. Mukhtar
    2018 | View in PubMed
  110. Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast.
     JM Wong, ML Piper, C Ewing, M Alvarado, LJ Esserman, H Sbitany, RD Foster, RA Mukhtar
    2018 | View in PubMed
  111. Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density.
     A Hosseini, AL Khoury, J Carter, JM Wong, MD Alvarado, C Ewing, LJ Esserman, RA Mukhtar
    2018 | View in PubMed
  112. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention.
     A Hosseini, LJ Esserman, AM Wallace, A Au, RA Mukhtar
    2018 | View in PubMed
  113. Breast tumor location in BRCA mutation carriers and implications for prevention.
     Ava Hosseini, Laura Esserman, Anne M. Wallace, Amal Khoury, Alfred Au, Rita Mukhtar
    2017 | View in PubMed
  114. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
     Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L
    2016 | View in PubMed
  115. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
     Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ
    2016 | View in PubMed
  116. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
     Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ
    2015 | View in PubMed
  117. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
     Mukhtar RA, Wong JM, Esserman LJ
    2015 | View in PubMed
  118. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
     Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ
    2013 | View in PubMed
  119. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
     Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ
    2013 | View in PubMed
  120. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
     Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators
    2012 | View in PubMed
  121. Biology of breast cancer in Nigerian women: a pilot study.
     Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ
    2012 | View in PubMed
  122. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
     Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ
    2012 | View in PubMed
  123. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
     RA Mukhtar, E Lips, J Wesseling, C Livasy, C Yau, D Berry, L van't Veer, LA Carey, LJ Esserman, S Rodenhuis, ES Hwang
    2011 | View in PubMed
  124. P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment.
     R Mukhtar, D Wolf, V Tandon, J Zhu, M Lenburg, Veer L van't, MJ Campbell
    2011 | View in PubMed
  125. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial.
     RA Mukhtar, N Hylton, M Rosen
    2011 | View in PubMed
  126. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
     Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ
    2011 | View in PubMed
  127. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.
     R. Mukhtar, A. P. Moore, V. Tandon, O. Nseyo, A. Au, F. L. Baehner, C. A. Adisa, N. Eleweke, O. I. Olopade, D. H. Moore, M. Campbell, L. Esserman
    2011 | View in PubMed
  128. Benign Thoracic Disease in the Elderly.
     Rita A. Mukhtar, Pierre R. Theodore
    2011 | View in PubMed
  129. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
     Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ
    2011 | View in PubMed
  130. Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy.
     RA Mukhtar, ES Hwang, C Livasy, LJ. Esserman
    2010 | View in PubMed
  131. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
     R. Mukhtar, A. Moore, O. Nseyo, A. Au, F. L. Baehner, D. H. Moore, M. Campbell, L. Esserman
    2010 | View in PubMed
  132. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence.
     Mukhtar RA, Baskin LS, Stock PG, Lee H
    2009 | View in PubMed
  133. Bacteriologic features of surgical site infections following breast surgery.
     Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, Chiu C, Hwang ES
    2009 | View in PubMed
  134. Benign thoracic disease in the elderly.
     Mukhtar RA, Theodore PR
    2009 | View in PubMed
  135. Variation in annual volume at a university hospital does not predict mortality for pancreatic resections.
     Mukhtar RA, Kattan OM, Harris HW
    2009 | View in PubMed
  136. Image of the month--quiz case. Traumatic intramuscular cyst of the duodenum.
     Spitzer AL, Mukhtar RA, Harris HW
    2005 | View in PubMed
  137. Quality-of-life issues in psoriasis.
     Mukhtar R, Choi J, Koo JY
    2004 | View in PubMed